Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Hajime Onuma"'
Publikováno v:
BJUI Compass, Vol 4, Iss 2, Pp 234-240 (2023)
Abstract Objectives This study aims to clarify the clinicopathological significance of several novel pathological markers, including the percentage of Gleason pattern 4 and small/non‐small cribriform pattern, in intermediate‐risk Gleason score 3
Externí odkaz:
https://doaj.org/article/70b691209b7346ed98f094f4df880d7e
Publikováno v:
BJUI Compass, Vol 2, Iss 3, Pp 169-177 (2021)
Abstract Objectives To determine the biological significance of zonal origins in prostate cancer. Patients and methods Altogether, 270 consecutive radical prostatectomy cases from 2009 to 2012 were adopted. Cases were divided into those having transi
Externí odkaz:
https://doaj.org/article/70cc48aec104425eaee7d97f70ec7265
Publikováno v:
BJUI Compass. 4:234-240
Autor:
Michie, Katsuta, Takahiro, Kimura, Kojiro, Tashiro, Masaya, Murakami, Kenichi, Hata, Takafumi, Yanagisawa, Hajime, Onuma, Toshihiro, Yamamoto, Shingo, Sugaya, Yoshinori, Watanabe, Yoshimasa, Nobeyama, Shin, Egawa, Akihiko, Asahina
Publikováno v:
Anticancer Research. 42:2023-2028
Therapeutic strategies for prostate cancer are currently undergoing a paradigm shift due to the advent of next-generation androgen receptor inhibitors. Among these inhibitors, apalutamide is regarded as a key drug because of its effectiveness. Howeve
Autor:
Hirotaka Suzuki, Takashi Otsuka, Takayuki Sano, Keigo Sakanaka, Tatsuya Shimomura, Keiichiro Miyajima, Takafumi Yanagisawa, Kenichi Hata, Wataru Fukuokaya, Yuki Enei, Shin Egawa, Akihiro Matsukawa, Yuya Iwamoto, Jun Miki, Shunsuke Tsuzuki, Hajime Onuma, Keiichiro Mori, Takahiro Kimura, Koki Obayashi
Publikováno v:
The Prostate. 82:3-12
BACKGROUND Although prostate cancer is a very common form of malignancy in men, the clinical significance of androgen deprivation therapy (ADT) with abiraterone acetate versus the nonsteroidal antiandrogen bicalutamide has not yet been verified in pa
Autor:
Hajime Onuma, Jun Miki, Hiroyuki Inaba, Hiroyuki Takahashi, Shin Egawa, Fumihiko Urabe, Shunsuke Tsuzuki, Kojiro Tashiro, Shoji Kimura, Takahiro Kimura, Wataru Fukuokaya, Akira Furuta, Shun Sato
Publikováno v:
Bladder Cancer. 7:205-211
BACKGROUND: The impact of incidental prostate cancer (IPC) on oncological outcomes after radical cystoprostatectomy (RCP) specimens from patients with bladder cancer (BC) remains controversial. This relationship has not been well elucidated in Asian
Publikováno v:
BJUI Compass, Vol 2, Iss 3, Pp 169-177 (2021)
Objectives To determine the biological significance of zonal origins in prostate cancer. Patients and methods Altogether, 270 consecutive radical prostatectomy cases from 2009 to 2012 were adopted. Cases were divided into those having transition zone
Autor:
Hirokazu Abe, Shunsuke Tsuzuki, Shoji Kimura, Masatoshi Tanaka, Hajime Onuma, Yuya Iwamoto, Takahiro Kimura, Fumihiko Urabe, Mariko Honda, Jun Miki, Wataru Fukuokaya, Yuki Enei, Yu Oyama, Takafumi Yanagisawa, Yuhei Koike, Shin Egawa
Publikováno v:
Targeted Oncology. 16:189-196
Subgroup analysis of KEYNOTE-045 suggested that cigarette smoking had a positive impact on the effectiveness of pembrolizumab in patients with advanced urothelial carcinoma (UC), whereas studies on other cancers treated with immune checkpoint inhibit
Autor:
Wataru Fukuokaya, Takafumi Yanagisawa, Masaki Hashimoto, Shutaro Yamamoto, Yuhei Koike, Yu Imai, Kosuke Iwatani, Hajime Onuma, Kagenori Ito, Fumihiko Urabe, Shunsuke Tsuzuki, Shoji Kimura, Jun Miki, Yu Oyama, Hirokazu Abe, Takahiro Kimura
BackgroundThe KEYNOTE-045 trial showed that pembrolizumab therapy improved the survival of patients with advanced urothelial carcinoma (UC). However, its effectiveness in trial-ineligible patients remains unclear.Materials and MethodsWe conducted a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42af18bd221b7d3634d2d0d926708772
https://doi.org/10.21203/rs.3.rs-1576583/v1
https://doi.org/10.21203/rs.3.rs-1576583/v1
Publikováno v:
Pathology International. 70:992-998
Expanding the inclusion criteria for active prostate cancer surveillance to include cases with a Gleason score (GS) of 3 + 4 = 7 has been discussed. GS 3 + 4 = 7 cases with a percentage of Gleason pattern 4 (%GP4)